FORXIGA® (dapagliflozin)

FORXIGA® is a highly selective SGLT2 inhibitor for type 2 diabetes mellitus, with 4-year safety and efficacy data, that removes glucose and its associated calories via the kidney.1

Dosing

One pill, once a day1

  • Can be taken any time, with or without food
  • Cost for 28-day supply is £36.5950

Licensed across the treatment pathway

FORXIGA® is licensed throughout the treatment pathway, from monotherapy** to insulin1

Dosing simplicity across the treatment pathway
Dosing simplicity across the treatment pathway

Adapted from FORXIGA® SmPC1

FORXIGA® 10 mg is licensed throughout the treatment pathway, from monotherapy to insulin. 

FORXIGA® 10 mg: Dosing
FORXIGA® 10 mg: Dosing

** Monotherapy: When diet and excercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.1

aFORXIGA® is not indicated for weight loss. Weight change was a secondary endpoint in clinical trials.1

The use of FORXIGA® with pioglitazone is not recommended.1